NASDAQ:TLRY

Tilray (TLRY) Stock Forecast, Price & News

$2.40

+0.02 (+0.84%)

(As of 05:42 PM ET)

Compare

Today's Range: $2.35
▼
$2.47
50-Day Range: $1.65
▼
$3.31
52-Week Range: $1.50
▼
$5.12

Volume: 18.99 million shs
Average Volume: 20.24 million shs
Market Capitalization: $1.69 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.07

Tilray MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 27.7% Upside
$3.07 Price Target
Short Interest: Healthy
12.67% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 16 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.18) to ($0.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Consumer Staples Sector

91st out of 123 stocks

Medicinals & Botanicals Industry

7th out of 11 stocks

3.0

Analyst's Opinion

Consensus Rating
Tilray has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.07, Tilray has a forecasted upside of 27.7% from its current price of $2.40.
Amount of Analyst Coverage
Tilray has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
12.67% of the outstanding shares of Tilray have been sold short.
Short Interest Ratio / Days to Cover
Tilray has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tilray has recently decreased by 6.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Tilray does not currently pay a dividend.
Dividend Growth
Tilray does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TLRY.

2.4

News and Social Media Coverage

News Sentiment
Tilray has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Consumer Staples companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Tilray this week, compared to 5 articles on an average week.
Search Interest
Only 77 people have searched for TLRY on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
MarketBeat Follows
37 people have added Tilray to their MarketBeat watchlist in the last 30 days. This is an increase of 147% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tilray insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.54% of the stock of Tilray is held by insiders.
Percentage Held by Institutions
Only 8.86% of the stock of Tilray is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Tilray are expected to grow in the coming year, from ($0.18) to ($0.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tilray is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tilray is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tilray has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tilray (NASDAQ:TLRY) Stock

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Nanaimo, Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

TLRY Price History

30 days | 90 days | 365 days | Advanced Chart

TLRY Stock News Headlines

September 12, 2023 | marketbeat.com

Cannabis Stocks: Green Gold Rush or Risk Off? (TLRY)

Cannabis stocks, including CGC, TLRY, and ACB, have experienced significant gains over the past month, posting double to triple-digit increases.

September 6, 2023 | marketbeat.com

Will This New Development Mean A Big Rally In Cannabis Stocks? (TLRY)

Numerous cannabis stocks surged after a government agency recommended removing marijuana from Schedule 1, potentially paving the way for industry growth.

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 22, 2023 | theglobeandmail.com

Closing Bell: Tilray Inc down on Thursday (TLRY)

September 22, 2023 | theglobeandmail.com

Tilray Brands: Top 10 Undervalued Growth Stocks on TSX (TLRY)

September 21, 2023 | markets.businessinsider.com

What's Going On With Tilray Brands Stock? Buzzkill

September 21, 2023 | seekingalpha.com

Tilray a top pick in Seeking Alpha Quant Ratings despite short interest

September 21, 2023 | finance.yahoo.com

Where Will Tilray Brands Be in 1 Year?

September 22, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

September 21, 2023 | finance.yahoo.com

Tilray Brands, Inc. to Announce First Quarter 2024 Financial Results on October 4, 2023

September 20, 2023 | finanznachrichten.de

Tilray Brands, Inc.: Tilray's Best-Selling Beers Make Landfall at Atlantis, Bahamas

September 19, 2023 | seekingalpha.com

Tilray: North America's Most Transformative Cannabis Company

September 18, 2023 | msn.com

TSX Declines; Tilray Shares Slide; BMO Announces Layoffs

September 18, 2023 | msn.com

Tilray Stock (NASDAQ:TLRY) Plunges 12.6% as Short Seller Foresees 70% Drop

September 18, 2023 | investing.com

Tilray, Inc. a 'failing cannabis player,' claims short-seller Kerrisdale Capital

September 18, 2023 | markets.businessinsider.com

What's Going On With Tilray Brands Stock? The Blunt Truth

September 18, 2023 | seekingalpha.com

Tilray Brands Is Potentially Very Overpriced

September 17, 2023 | americanbankingnews.com

Tilray (NASDAQ:TLRY) Shares Gap Up to $2.98

September 16, 2023 | americanbankingnews.com

Tilray Sees Unusually High Options Volume (NASDAQ:TLRY)

September 15, 2023 | benzinga.com

Entourage Extends Supply Deal With Tilray's HEXO To Ensure Top-Quality Cannabis Products

September 15, 2023 | americanbankingnews.com

Tilray Inc (NASDAQ:TLRY) Receives Consensus Recommendation of "Hold" from Analysts

September 14, 2023 | benzinga.com

Tilray's Beer Business Expands Nationally, Starting In This State

September 12, 2023 | benzinga.com

Why Tilray Brands Stock Is Moving

September 8, 2023 | investorplace.com

TLRY Outlook: How Tilray Fits in the Cannabis Stocks Puzzle

September 5, 2023 | benzinga.com

Why Tilray Brands Stock Is Up 40% Over The Past Week

September 5, 2023 | investorplace.com

Why Is Tilray (TLRY) Stock Up 7% Today?

September 3, 2023 | investorplace.com

Tilray’s Cannabis Beverage Move: Is It Time to Buy, Hold or Sell?

See More Headlines

Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Company Calendar

Last Earnings: 4/10/2023
Today: 9/22/2023
Next Earnings (Confirmed): 10/04/2023
Fiscal Year End: 5/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medicinals & botanicals
Sub-Industry: N/A
Sector: Consumer Staples
Current Symbol: NASDAQ:TLRY
CUSIP: N/A
CIK: 1731348
Web: www.tilray.com
Phone: 206-432-9325
Fax: N/A
Employees: 1,600
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.07
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +27.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,452,660,000.00
Net Margins: -226.15%
Pretax Margin: -231.24%
Return on Equity: -3.45%
Return on Assets: -2.76%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 1.79
Quick Ratio: 1.32

Sales & Book Value

Annual Sales: $627.12 million
Price / Sales: 2.69
Cash Flow: $0.00 per share
Price / Cash Flow: 2,721.34
Book Value: $5.07 per share
Price / Book: 0.47

Miscellaneous

Outstanding Shares: 703,260,000
Free Float: 685,394,000
Market Cap: $1.69 billion
Optionable: Optionable
Beta: 2.39

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Edward Wood Pastorius Jr. (Age 50)
Chief Revenue Officer

Mr. Brendan Kennedy (Age 46)
Pres, CEO & Director

Mr. Mark Castaneda (Age 53)
CFO, Sec. & Treasurer

Dr. Catherine Jacobson
Director of Clinical Research & Member of Medical Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TLRY Stock - Frequently Asked Questions

Should I buy or sell Tilray stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings or view top-rated stocks.
What is Tilray's stock price forecast for 2023?: 8 Wall Street research analysts have issued 1-year price objectives for Tilray's stock. Their TLRY share price forecasts range from $2.00 to $5.00. On average, they expect the company's stock price to reach $3.07 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for TLRY or view top-rated stocks among Wall Street analysts.
How have TLRY shares performed in 2023?: Tilray's stock was trading at $2.69 at the beginning of the year. Since then, TLRY shares have decreased by 10.8% and is now trading at $2.40.
View the best growth stocks for 2023 here.
When is Tilray's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our TLRY earnings forecast.
How can I listen to Tilray's earnings call?: Tilray will be holding an earnings conference call on Wednesday, October 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Tilray's earnings last quarter?: Tilray Inc (NASDAQ:TLRY) released its quarterly earnings data on Monday, April, 10th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $1.84. The company earned $145.59 million during the quarter, compared to analyst estimates of $150.13 million. Tilray had a negative trailing twelve-month return on equity of 3.45% and a negative net margin of 226.15%. The company's revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.04 EPS.
What ETFs hold Tilray's stock?: ETFs with the largest weight of Tilray (NASDAQ:TLRY) stock in their portfolio include Global X Cannabis ETF (POTX), Amplify Seymour Cannabis ETF (CNBS), ETFMG Alternative Harvest ETF (MJ), Cambria Cannabis ETF (TOKE), AdvisorShares Pure Cannabis ETF (YOLO), B.A.D. Etf (BAD), AXS Cannabis ETF (THCX) and SoFi Social 50 ETF (SFYF).
What is Brendan Kennedy's approval rating as Tilray's CEO?: 32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).
When did Tilray IPO?: (TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.
What is Tilray's stock symbol?: Tilray trades on the NASDAQ under the ticker symbol "TLRY."
Who are Tilray's major shareholders?: Tilray's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (1.51%), Mirae Asset Global Investments Co. Ltd. (0.43%), BlackRock Inc. (0.38%), Swiss National Bank (0.20%), State Street Corp (0.19%) and TD Asset Management Inc (0.16%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Christine StClare and James R Meiers.
View institutional ownership trends.
How do I buy shares of Tilray?: Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tilray's stock price today?: One share of TLRY stock can currently be purchased for approximately $2.40.
How much money does Tilray make?: Tilray (NASDAQ:TLRY) has a market capitalization of $1.69 billion and generates $627.12 million in revenue each year. The company earns $-1,452,660,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.
How many employees does Tilray have?: The company employs 1,600 workers across the globe.
How can I contact Tilray?: Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for the company is www.tilray.com. The company can be reached via phone at 206-432-9325.

This page (NASDAQ:TLRY) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial